Low CXCL12 expression maintained a high hazard rate for whole-AML patients (HR = 2.25, 95% CI [1.51–3.35], P < 0.0001), after adjusting age (P < 0.0001), WBC count (P < 0.0001), cytogenetic risk (P = 0.002) and mutation status of TP53 (P = 0.004), RUNX1 (P = 0.023) and DNMT3A (P = 0.012). This evidence concerns the gene DNMT3A and acute myeloid leukemia.